Uso de dalbavancina en pacientes en hemodiálisis con infecciones protésicas endovasculares por microorganismos multirresistente.

  1. Elena Borrego García 1
  2. Andrés Luis Ruiz Sancho 2
  3. Alejandro Peña Monje 3
  4. David Vinuesa García 4
  5. María Núñez Núñez 5
  6. José Hernández Quero 5
  1. 1 S. Nefrología Hospital Universitario San Cecilio, Granada
  2. 2 Unidad de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Granada
  3. 3 S. Microbiología Hospital Universitario San Cecilio, Granada
  4. 4 Farmacología hospitalaria,Hospital, Universitario San Cecilio, Granada
  5. 5 Universitario San Cecilio, Granada
Show affiliations +
Journal:
Diálisis y trasplante: publicación oficial de la Sociedad Española de Diálisis y Trasplante

ISSN: 1886-2845

Year of publication: 2020

Volume: 41

Issue: 2

Pages: 18-20

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Diálisis y trasplante: publicación oficial de la Sociedad Española de Diálisis y Trasplante

Abstract

Dalbavancin is a new semi-synthetic derivative lipoglycopeptide antibiotic of teicoplanin with an efficacy profile superior to this. The structure size is high, which determines its pharmacokinetic profile1. It is mixed through non-microsomal metabolism with inactive metabolites, and renal by glomerular filtration. Patients with mild-moderate renal impairment and in hemodyalisis do not require dose adjustment (GF >30-79ml/min), and can be administered without taking into account hemodialysis times2. In cases with clearance <30ml / min and without hemodialysis program, the recommended dose should be reduced to 750mg / week, followed 375mg a week later. We present two cases of infection in our hemodialysis area who were prescribed this antibiotic in the presence of multidrugresistant microorganisms and with infection-free status after long guidelines with dalbavancin.

Data source: Dialnet